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Abstract 
Gabapentin (GBP) is a cyclic y-aminobutyric acid (GABA) analog and investigational antiepileptic drug which is effective in the 
treatment of a variety of human and experimental seizures. GBP’s antiepileptic mechanism of action is not known. The present studies 
tested for effects of GBP on inhibitory (GABA and glycine) and excitatory (N-methyl-o-aspartate (NMDA) and non-NMDA) amino 
acid neurotransmitter receptors, on repetitive tiring of sodium (Na+) action potentials, and on voltage-dependent calcium (Ca”) 
channel currents in cultured rodent neurons using intracellular, whole cell, or single channel recording techniques. GBP did not have a 
significant effect in any experiment when tested at or above concentrations that are therapeutic in humans except for a variable 
enhancement of NMDA-evoked depolarizations. These results suggest that the antiepileptic activity of GBP is not due to direct effects at 
receptors for inhibitory or excitatory amino acids or on voltage-dependent Na+ or Ca2+ channels. 
Key words: Gabapentin; Investigational antiepileptic drug; Repetitive tiring; GABA; Glycine; N-Methyl-o-aspartate; Sodium action 
potentials; Calcium currents; Voltage clamp; Single channel 
1. Introduction 
Gabapentin (GBP), I-(aminomethyl) cyclohex- 
ane-acetic acid, is a cyclic y-aminobutyric acid 
(GABA) analog originally designed to mimic the 
steric conformation of GABA [22], to have high 
lipid solubility to penetrate the blood-brain bar- 
rier, and to be a centrally active GABA agonist 
with potential therapeutic value [19]. GBP has 
been shown to have anticonvulsant activity in a 
variety of animal seizure models [3] and is effec- 
tive in the treatment of human partial [5,7,11,23] 
and generalized tonic-clonic seizures [5,7]. Despite 
its effectiveness against a variety of seizures, GBP’s 
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antiepileptic mechanism of action remains un- 
known. 
There are relatively few reported electrophysiolo- 
gical studies directed at determining GBP’s antiepi- 
leptic mechanism of action. The present study used 
a variety of cultured rodent neuronal preparations 
and electrophysiological techniques including in- 
tracellular, whole cell, and single channel record- 
ings to determine any effects of GBP on inhibitory 
(GABA and glycine) and excitatory (N-methyl-D- 
aspartate (NMDA) and non-NMDA) amino acid 
neurotransmitter receptors, repetitive tiring of so- 
dium (Na+) action potentials, and on voltage-de- 
pendent calcium (Ca2’) channel currents. GBP 
was tested at or above plasma concentrations 
which range N 12-88 ,uM in ongoing clinical stu- 
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dies [6]. These studies were chosen to corroborate 
or confirm the results of other studies suggesting 
an effect of GBP on excitatory or inhibitory neuro- 
transmitter systems, or on voltage-dependent ion 
channels. Preliminary results from;the present ex- 
periments have been reported previously [ 13,261. 
removed, placed in MEM, centrifuged, triturated, 
recentrifuged, resuspended, plated, reincubated, 
and 1 ml of MEM was added to each plate after 
30 min. Nodose and DRG neurons were used after 
_ 1 h of incubation and were viable for - 12 h. 
2.2. Experiments 
2. Methods 
2. I. Cultures 
2. I. I. Cortical neurons. Cortices were removed 
from E 18 rat fetuses, treated with trypsin (type 1, 
bovine pancreas, Sigma) and mechanically disso- 
ciated. Neurons were suspended in MEM supple- 
mented with glucose 30 mM, bicarbonate 26 mM, 
10% fetal calf serum and 10% horse serum and 
were plated on poly+lysine-coated culture dishes. 
5-Fluoro-2-deoxyuridine (15 pg/ml) and uridine 
(35 pg/ml) in MEM were added to cultures on the 
fifth day. Cultures were maintained for 2-5 weeks 
prior to experiments. 
2.1.2. Spinal cord neurons. Spinal cords were dis- 
sected from E 12-14 mouse fetuses, minced, me- 
chanically dissociated, and plated. Growth media 
consisted of MEM supplemented with 5.5 g glu- 
cose and 1.5 g NaHCOj per liter, sera as above 
and adjusted to 325 mOsm. The cultures were in- 
cubated at 35°C in a 90% air/IO% CO* atmo- 
sphere. The NaC03/C02 buffer was maintained at 
pH 7.4. 5-Fluoro-2-deoxyuridine was added to cul- 
tures after 68 days. Cultures were maintained for 
at least 4 weeks prior to experiments. 
2.1.3. Sensory neurons. Nodose ganglia were ta- 
ken from 5-10 days old rats, placed in oxygenated 
Ca2+- and Mgzf -free DPBS, treated with collage- 
nase (type lA, Sigma) (1 mg/ml), and incubated at 
37°C in a 93% sir/7% CO2 atmosphere for 30 min. 
Following addition of 5% fetal calf serum, the neu- 
rons were triturated, centrifuged, resuspended in 
MEM, plated in collagen-coated dishes, and rein- 
cubated prior to use. Dorsal root ganglia (DRG) 
were taken from 15-25 day old rats (-20/animal), 
placed in MEM, minced, treated with collagenase 
(3 mg/ml), and incubated for 50 min before trypsin 
(1 mg/ml) was added for 10 min. The ganglia were 
2.2.1. Inhibitory and excitatory amino acids. In- 
tracellular recordings of spinal cord or cortical 
neurons were made with glass micropipettes (2s 
60 MQ) tilled with 3 M KC1 (GABA and glycine) 
or 4 M KAc (glutamate). Membrane potential was 
recorded with a high-impedance bridge amplifier 
and recorded on analog tape. The recording solu- 
tion contained (in mM): NaCl 140, KC1 5, MgClz 
10, CaC12 1, glucose 10, pH 7.3-7.4. GABA (0.5 
M, pH 3.2, positive current), glycine (0.5 M, pH 
3.0, positive current), or glutamate (0.4 M, pH 10, 
negative current) was applied by passing 400 ms 
current pulses every 5 s from a high resistance mi- 
cropipette placed - 2 pm from the impaled neuron. 
Retaining current (negative for GABA and glycine, 
positive for glutamate) was applied to prevent 
leakage between pulses. Membrane potential was 
hyperpolarized to - 60 to - 80 mV. Iontophoretic 
current was adjusted so that responses were ap- 
proximately 10 mV in amplitude. GBP was ap- 
plied by pressure ejection (0.25 1.0 psi, 30 s) from 
blunt-tipped (10 pm) micropipettes placed 3&100 
pm from the neuron. NMDA (10 PM) was applied 
by pressure ejection (10 s, 1 psi) in the presence or 
absence of GBP or glycine. Data were expressed as 
percentage of control amplitude but were not used 
if the response failed to return to control levels 
after drug application. 
2.2.2. NMDA single channel currents. The exter- 
nal solution for single channel experiments con- 
sisted of (in mM): NaCl 142, KC1 1.5, CaC12 1, 
glucose 10, Na’-HEPES 10 (pH 7.4, -300-320 
mOsm). The internal pipette solution consisted of 
(in mM): CsCl 153, Cs’-HEPES 10, EGTA 5 (pH 
7.4, -280-305 mOsm). NMDA (Sigma) and gly- 
tine (Sigma) were dissolved in external solution 
(lo-100 PM) and serially diluted to final concen- 
trations. Glycine concentrations were expressed as 
the amount of glycine added to the external solu- 
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tion. Drugs were applied to membrane patches by 
pressure ejection (0.25-l .O psi) from blunt-tipped 
(15-25 pm) glass micropipettes positioned N 50 
pm from the patch. 
Cultures were maintained at room temperature 
(2&23”(Z) and were superfused at approximately 1 
ml/min during or between recordings. High resis- 
tance GQ seals were obtained with glass micropip- 
ettes (5-10 MS2) for outside-out excised patch re- 
cordings. Recordings were performed with a L/M 
EPC-7 amplifier (LIST-Medical Instruments) and 
currents were recorded on a video cassette system 
via a digital audio processor (16 bit, 44 kHz). Cur- 
rents were simultaneously displayed on a chart re- 
corder using a lowpass (3 db at 1 kHz) S-pole Bes- 
sel filter. Data were played back from the VCR 
system through a lowpass filter (3 db at 2 kHz) 
and digitized (20 kHz, 16 bit) for computer analy- 
sis. System dead time was 70 ps, so only openings 
> 140 ~.ls (2 x system dead time) were considered 
valid openings. 
Single channel data were analyzed by computer 
using a locally written channel detection program 
(50% threshold crossing criterion) and locally writ- 
ten analysis programs used to determine opening 
frequency, and open and closed durations. Percent 
change in opening frequency was determined in 
those patches where control solution (NMDA 
alone) was applied before, during and after appli- 
cation of GBP. Openings from the two higher con- 
ductance levels of NMDA receptor single channel 
currents (40 and 50 pS) were analyzed. 
2.2.3. Repetitive firing and spontaneous synaptically 
driven Na+ action potentials. Intracellular record- 
ings of spinal cord neurons were made in a manner 
similar to those in the inhibitory and excitatory 
amino acid experiments. Only cultures in which all 
neurons exhibited sustained repetitive tiring and 
spontaneous action potentials (3-5 neurons exam- 
ined per culture) in control medium were used for 
experiments. To elicit repetitive firing, 450 ms de- 
polarizing current pulses of varying amplitudes 
were used. If a neuron fired action potentials 
throughout any of the 450 ms pulses, tiring was 
judged as sustained. A neuron was used when the 
resting membrane potential was -40 mV or more 
negative and had overshooting action potentials. 
All experiments were conducted at 35-37°C. GBP 
was dissolved in recording solution and was ap- 
plied to the bath. Neurons were tested at mem- 
brane potentials of approximately -50 mV for 
the ability to fire sustained action potentials. Data 
were expressed as the percentage of neurons show- 
ing sustained firing. Because recordings were done 
with a low concentration of Mg*+ in the recording 
solution, synaptically driven action potentials were 
recorded when neurons were held at resting poten- 
tial (- 50 to - 60 mV). Effects of GBP on sponta- 
neous action potentials were qualitatively assessed 
and cells were judged to have either normal or re- 
duced levels of spontaneous action potentials. 
2.2.4. Voltage-dependent Ca2+ channel currents. 
Recordings of Ca*+ currents were made with 
glass micropipettes (1.5-2.5 MQ) filled with a solu- 
tion of (in mM): CsCl 140, CsOH 30, HEPES 10, 
EGTA 10, ATP 5 and GTP 0.1, pH 7.2-7.3, N 300 
mOsm. Neurons were bathed in a solution of (in 
mM): choline Cl 67, TEA 100, glucose 5.6, KC1 
5.3, CaC12 5.0, MgC12 0.8, HEPES 10, pH 7.35, 
-320 mOsm. Following sealing of the micropip- 
ette to the neuron and rupture of the membrane 
patch, the neuron was hyperpolarized to a holding 
potential (V,) = -90 mV. The program 
pCLAMP (Axon Instruments) was used to gener- 
ate voltage step commands and to digitize (5.6 
kHz) and store current traces. All experiments 
were conducted at room temperature. GBP was 
prepared on the day of experiments as described 
above and put in external solution. The GBP solu- 
tion was drawn up into a blunt tipped (15-20 pm) 
micropipette and lowered to -50 pm from the 
neuronal soma and applied by passive diffusion or 
pressure ejection (1 psi) shortly before and during 
voltage step commands. 
T currents were isolated by evoking currents 
from a Vh = -90 mV at clamp potentials (V,) at 
or positive to - 55 mV (typically, V, = -65 to 
-20 mV). N/L currents were evoked from a Vi, 
= - 80 or - 90 mV at a V, at or positive to - 20 
mV. T and N/L currents were measured at the 
point of peak inward current and at 100 ms, and 
were leak subtracted for analysis. In order to dis- 
tinguish between the N and L components qualita- 
tively, currents were evoked at V, = - 10 mV 
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Fig. 1. GBP had no effect on iontophoretic GABA and gluta- 
mate responses in cultured spinal cord neurons. Traces repre- 
sent intracellular recordings of membrane depolarizations that 
were evoked by the application of GABA (upper) and glutamate 
(lower). Application of GBP did not change the amplitude of 
membrane depolarizations. 
from Vh = - 80 mV and -40 mV. Current 
evoked from Vh = -40 mV was used as an esti- 
mate of L current and the additional current 
evoked from Vi, = -80 mV was used as an esti- 
mate of N current. Ethosuximide (1 mM) was used 
to block T current; nifedipine (10 PM) was used to 
block L current; w-conotoxin GVIA (10 ,uM) was 
used to block N current. Each was applied by pas- 
sive diffusion from blunt tipped (35-50 PM) micro- 
pipettes positioned -50 pm from the neuronal 
soma prior to voltage step commands. 
3. Results 
3.1. GBP did not affect membrane potential 
GBP (18-500 PM) did not affect membrane po- 
tential upon direct application to spinal cord neu- 
rons (N = 20). No depolarization or hyperpolariza- 
tion was noted upon application, unlike the action 
of agonists that interact with GABA* or glutamate 
receptors which produce depolarization or hyper- 
polarization, depending upon recording condi- 
tions. These results suggest that GBP is not acting 
as an agonist at inhibitory or excitatory amino acid 
receptors in spinal cord neurons. 
3.2. GBP did not affect inhibitory amino acid 
responses 
Iontophoretic application of GABA or glycine, 
with 3 M KC1 in the recording electrode, resulted 
in a depolarization of membrane potential. Ionto- 
phoretic ejection current was adjusted to produce 
depolarization of approximately 10 mV. GBP (18- 
500 PM) applied by pressure ejection did not re- 
duce the amplitude of GABA- or glycine-evoked 
depolarizations (Fig. 1, Table 1). Diazepam (100 
nM) increased the amplitude of iontophoretic 
GABA responses by 81% (N = 5) in a similar pre- 
paration. 
3.3. GBP had variable effects on excitatory amino 
acid responses 
Iontophoretic application of glutamate in the 
presence of Mg2+ (10 mM) activates both a-ami- 
no-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA) and kainate subtypes of postsynaptic glu- 
TABLE I 
Effect of GBP on inhibitory and excitatory neurotransmitter responses in cultured fetal cortical (ctx) and spinal cord (SC) neurons 
Prep. Agonist application GBP (PM) % Control (SEM, N) 
GABA SC ionto 18 100 f 1.5 (N=5) 
50 103 f 2.3 (N=5) 
Glutamate SC ionto 175 98 + 1.5 (N=5) 
Glycine ctx ionto 500 99 + 3.1 (N=5) 
NMDA ctx local 10 PM (f 1 PM glycine) 100 159 + 18.0 (N= 18)’ 
106 &- 6.4 (N=6) 
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Fig. 2. GBP had some effect on the amplitude of NMDA- 
evoked depolarizations in the absence of added glycine in cul- 
tured cortical neurons. Traces represent intracellular recordings 
of membrane depolarizations evoked by the local application of 
NMDA (upper) or in combination with GBP (lower). The am- 
plitude of the NMDA-evoked depolarization at the end of the 
application was measured. The left panel (A) is an example of a 
neuron where the addition of GBP resulted in an increase in the 
amplitude of the sustained portion of the depolarization. No 
effect was seen in the neuron represented in B tested under the 
same conditions. 
tamate receptors. GBP (175 PM) applied by pres- 
sure ejection had no effect on the amplitude of 
iontophoretic glutamate responses (Fig. 1, Table 
1). Pentobarbital (200 PM) reduced the amplitude 
of glutamate responses by 16% (N = 5). 
However, GBP (100 PM) had a variable effect on 
the responses of cortical neurons when applied 
with NMDA (Table 1, Fig. 2). In the absence of 
added glycine, GBP enhanced the amplitude of 
the sustained portion of NMDA-evoked responses 
in seven of 18 neurons with an average increase of 
59% (Fig. 2A). Eleven of 18 cells showed no en- 
hancement (~20% change from control) of 
NMDA responses by 100 ,LM GBP (Fig. 2B). Gly- 
tine was effective in enhancing NMDA-evoked de- 
polarizations in all neurons tested with the addi- 
tion of glycine (1 PM) enhancing the amplitude of 
the sustained portion of NMDA-evoked depolari- 
zations by 212% (N = 4). 
GBP did not enhance NMDA-evoked depolari- 
zations in the presence of glycine. With glycine (1 
,nM), GBP at 100 PM (106% of control, N = 6) or 
at 1 mM (104% of control, N = 10) was not effec- 
tive in enhancing NMDA-evoked depolarizations 
when applied by pressure ejection. Application of 
1 mM GBP by superfusion was also ineffective in 
affecting NMDA-evoked depolarizations (106 f 
3.1% control, N= 5). At higher concentrations of 
NMDA (25 PM) and glycine (10 PM), GBP at 10 
,LM (107 f 9.8% control, N= 5) and 100 PM (104 
f 7.5% control) had no effect on the amplitude of 
the sustained portion of the NMDA-evoked depo- 
larizations. 
GBP did not reduce the amplitude of NMDA- 
evoked depolarizations under any of the condi- 
tions tested. However, NMDA (10 PM) responses 
could be completely blocked by the competitive 
NMDA antagonist 3-(( f. )-2-carboxypiperazin-4- 
yl)-propyl- 1 -phosphonic acid (CPP) (100 PM, 
N = 3) and the amplitude of the sustained portion 
of NMDA-evoked depolarizations was reduced to 
9 f 4.5% of control by the glycine site partial 
agonist HA-966 (500 PM, N = 6). 
Single channel recordings of NMDA receptor 
currents from excised outside-out patches were 
made to further investigate the possibility of an 
interaction between GBP and NMDA receptors. 
In the absence of added glycine NMDA (5 PM) 
evoked single channel openings at a frequency of 
2.2/s. Addition of 1 mM GBP did not increase the 
frequency of openings (1.4/s) in these patches but 
the frequency of NMDA receptor channel open- 
ings was increased 5-fold (10.4/s) by the addition 
of 2.5 PM glycine (N=4 patches). In the presence 
of 2.5 PM glycine, GBP (1 mM) did not change 
average open duration (2.6 ms control, 2.5 ms 
GBP), opening frequency (10.7/s control, 9.9/s 
GBP), burst duration (6.7 ms control, 7.5 ms 
GPB), the number of openings/burst (1.7 control, 
1.9 GBP) or the burst frequency (6.0/s control, 5.3/ 
s GBP) (N = 6 patches, 28949159 openings, 1682- 
4824 bursts, Fig. 3). GBP did not alter the ampli- 
tude of NMDA receptor single channel openings in 
the presence or absence of glycine (Fig. 3). These 
data indicate that GBP does not act like an agonist 
or partial agonist at the glycine site of the NMDA 
receptor, having no effect on the frequency of 
channel openings, and that GBP also had no ef- 















Fig. 3. GBP did not act like an agonist or antagonist at the 
glycine site of the NMDA receptor in single channel recordings 
from outside-out excised patches. In the absence of added gly- 
tine (A), NMDA (5 PM) evoked very few openings of NMDA 
receptor single channels. Addition of GBP (I mM) had little 
effect on opening frequency while addition of glycine (2.5 PM) 
greatly increased the frequency of channel opening. In the pre- 
sence of NMDA and glycine (B), addition of GBP (I mM) had 
no effect on the kinetics of single channel openings. 
3.4. GBP did not block sustained repetitive firing of 
Nai action potentials or synaptically driven action 
potentials 
Control neurons (N = 17) responded to 4.50 ms 
depolarizations with trains of action potentials 
that were sustained throughout the depolarization 
(Fig. 4, left panel). Addition of GBP (18-175 PM) 
to the bathing solution for l&30 min had no effect 
on the sustained repetitive firing of action poten- 
tials (Table 2, Fig. 4, right panel). In experiments 
performed in low Mg2 ’ (1 mM), the effect of GBP 
on spontaneous synaptically driven action poten- 
TABLE 2 
Effect of GBP on sustained repetitive firing and spontaneous 
synaptically driven action potentials in cultured fetal spinal cord 
neurons 
GBP (PM) % of neurons with % of neurons with 
sustained repetitive normal spontaneous 
tiring (N) activity (N) 
0 (control) 100 (17) 100 (29) 
I8 100 (7) 82 (II) 
50 100 (IO) 73 (15) 
175 88 (8) 90 (IO) 
* 
1.5nA 
Control Gabapentin (175 PM) 
Fig. 4. GBP had no effect on sustained repetitive tiring of Na + 
action potentials in cultured spinal cord neurons. In control (left 
panel), membrane depolarization was increased by increasing 
the magnitude of injected current (current magnitudes indi- 
cated at the right of each trace (nA)) resulting in an increase in 
the number and frequency of action potentials. In a recording of 
a different neuron, application of GBP (I 75 PM) made no dif- 
ference in the ability of the neuron to fire a sustained train of 
action potentials. Resting membrane potential was -50 mV 
(control) and - 55 mV (GBP). 
tials was evaluated. Bath application of GBP ( 18- 
175 PM) had no effect on spontaneous action po- 
tentials (Table 2). 
3.5. GBP did not ajjhct Ca’ ’ channel currents 
GBP (I mM) was tested for effects on Ca2+ chan- 
nel currents in nodose and dorsal root ganglion neu- 
rons (N = 18). Low threshold (T) and high threshold 
(N/L) currents were examined individually. GBP 
had no effect on peak current, current at 100 ms, 
or on apparent current activation or inactivation 
(Fig. 5). Individual Ca2+ channel currents were re- 
duced by the application of specific blockers. Etho- 
suximide (1 mM) reduced peak T current (16%, 
N = 3). Nifedipine (10 PM) reduced L current (30% 
of evoked current from Vh = -40 mV at a V, = 
- 10 mV, N = 3). w-Conotoxin (10 PM) reduced N 
current (45% of evoked current from Vh = -90 
mV at V, = - 10 mV, N = 3) (data not shown). 




Control, Gabapentin 1 mM 
Vc=-10mV 
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Fig. 5. GBP had no effect on low (T) (left) or high (N/L) (right) 
threshold Ca’+ channel currents in dorsal root ganglion neu- 
rons. GBP (1 mM) did not affect peak current, current at 100 
ms, current activation or inactivation. V,, clamp potential; Vh, 
holding potential. 
4. Discussion 
GBP was designed to have a steric conformation 
similar to GABA and to have high lipid solubility 
to penetrate the blood-brain barrier for potential 
therapeutic value as a GABA agonist. GBP has 
shown potent anticonvulsant activity in a variety 
of animal seizure models and is effective in treat- 
ing human partial and generalized tonic-clonic sei- 
zures. Several types of experimental studies have 
been performed to determine the nature of GBP’s 
antiepileptic effects. These studies include possible 
interaction with ligand- and voltage-gated ions 
channels. Inhibitory and excitatory amino acid re- 
ceptor systems have been examined extensively 
without conclusive results. Fewer studies have 
been directed at voltage-gated ion channels yield- 
ing negative or inconclusive results. 
4.1. Inhibitory amino acid systems 
Early work suggested that GBP may act on 
GABA systems since it protected mice from tonic 
extension in chemical convulsion models directed 
at inhibition of GABA synthesis (3-mercaptopro- 
pionic acid. isonicotinic acid, semicarbazide) or in- 
hibition at the GABA* receptor complex (bicucul- 
line, picrotoxin) [2,4]. However, subsequent work 
has not clearly demonstrated a specific effect of 
GBP on GABAergic systems. The inhibition of 
monoamine release by GBP in electrically stimu- 
lated rabbit caudate nucleus [18] and rat cortex 
[21] was not modified by GABA, baclofen, or bi- 
cuculline suggesting that GBP’s action was not at 
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GABAA or GABAa receptors. Binding experi- 
ments in rat brain and spinal cord have shown 
that GBP has no significant affinity to the GA- 
BAA or GABAn binding sites measured by ‘H- 
muscimol and 3H-baclofen displacement, respec- 
tively. GBP did not significantly inhibit the bind- 
ing of 3H-diazepam, had only a weak inhibitory 
effect on the GABA degrading enzyme GABA- 
aminotransferase, did not elevate GABA content 
in nerve terminals, and did not affect the GABA 
uptake system [3]. However, GBP has been shown 
to increase GABA turnover in several regions of 
rat brain [15] and recent work has shown that 
GBP binds to a novel high-affinity site in the cen- 
tral nervous system [12,25] and is potently dis- 
placed by the anticonvulsant 3-isobutyl GABA 
[27]. Additionally, GBP has been shown to be a 
substrate for a saturable L-amino acid transport 
system in rat gut tissues [24]. 
In electrophysiological studies, GBP did not af- 
fect depolarizations elicited by iontophoretic appli- 
cation of GABA on cultured mouse spinal cord 
neurons in the present study or previously [26] 
although a use-dependent reduction of GABA re- 
sponses has been reported [29]. Additionally, GBP 
appeared to act by GABA receptor-independent 
mechanisms in studies with rat hippocampal slices 
[IO] and the feline trigeminal nucleus [14]. GBP has 
been shown to decrease the inhibition evoked by 
paired-pulse orthodromic stimulation of pyrami- 
dal neurons in the hippocampal slice preparation 
[8,26] in a manner similar to that of phenytoin. 
This stimulation paradigm is used to evaluate the 
effect of activating inhibitory neurons via GA- 
BAergic mechanisms, however, the specific effect 
of GBP is not known. 
GBP protected mice from convulsions caused by 
strychnine, a glycine receptor antagonist, but was 
unable to displace 3H-strychnine in binding studies 
at the highest concentrations tested [3]. The present 
studies showed no effect of GBP on the response of 
spinal cord neurons to iontophoretically applied 
glycine. 
4.2. Excitatory amino acid systems 
GBP has been tested in animal seizure models 
where seizures are induced by administration of 
excitatory amino acids. GBP prolonged the onset 
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latency of clonic convulsions and tonic extension 
and death in mice following intraperitoneal (i.p.) 
injections of NMDA, but not kainic acid or quino- 
linic acid. GBP did not have a clear effect on con- 
vulsions when these compounds or glutamate were 
injected into the lateral ventricle of rats [l]. 1.~. 
injections in mice of GBP or the NMDA receptor 
competitive antagonist CPP antagonized tonic sei- 
zures. The effect of GBP, but not CPP, was dose- 
dependently antagonized by the administration of 
serine, a glycine receptor agonist, suggesting an 
involvement of the strychnine-insensitive glycine 
site of the NMDA receptor in the anticonvulsant 
activity of GBP [17]. 
In unpublished studies, GBP reportedly antago- 
nized NMDA-, but not kainate-induced depolari- 
zations in thalamic and hippocampal slice prepara- 
tions, and antagonized NMDA-induced currents in 
the presence of glycine in cultured striatal neurons, 
an effect that was reversible by the addition of 
serine or increased glycine [6]. The present studies 
did not show a significant effect of GBP on neuro- 
nal responses to iontophoretic application of gluta- 
mate and did not block membrane depolarizations 
and single channel currents evoked by NMDA 
with or without coapplication of glycine. These 
results, in part, are similar to the findings of 
others where GBP had no effect on spinal cord 
neuron depolarizations elicited by iontophoreti- 
tally applied glutamate [26] or pressure-ejected 
NMDA [28]. Additionally, in extracellular record- 
ings from rat hippocampal slice preparations, GBP 
had no effect on long-term potentiation making it 
unlike antagonists of the NMDA receptor [26]. 
GBP (100 PM) also did not reduce the neuronal 
damage that occurs following brief applications of 
500 PM glutamate to rat cortical cell cultures, a 
paradigm where competitive, noncompetitive and 
glycine-site NMDA antagonists effectively block 
glutamate-induced cell damage (D. Rock and G. 
Campbell, unpublished observations). These re- 
sults suggest that the anticonvulsant action of 
GBP is not due to an effect on excitatory amino 
acid receptors. 
4.3. Voltage-gated channels 
Sustained repetitive firing @RF) of action poten- 
tials in neurons can be inhibited by antiepileptic 
drugs that block the voltage-dependent Na+ chan- 
nel [16]. GBP had no effect on SRF in the present 
studies or previously [26] using mouse spinal cord 
neurons. In preliminary experiments using the 
same neuronal preparation, high concentrations of 
GBP (100 ,nM) reduced SRF and following over- 
night exposure of the cultures to GBP, SRF was 
reduced by GBP (1 PM) [29]. The significance of 
these findings is not fully established at this time. 
Recent voltage clamp experiments on Chinese 
hamster ovary cells with stably expressed c( sub- 
units of voltage-dependent Nat channels suggest 
that GBP does not interact directly with Na+ 
channels (C. Taylor, personal communication). 
Voltage-dependent Ca2’ channel currents are in- 
volved in numerous physiologic functions of the 
neuron. L currents are involved in the presynaptic 
release of neurotransmitters, N currents may be pri- 
mary regulators of the inhibition of release of neu- 
rotransmitters or neuromodulators, and T currents 
are probably responsible for the low threshold 
Ca2+ spike that underlies some neuronal oscilla- 
tory bursting behavior. T currents may also be in- 
volved in the generation of thalamocortical 
rhythms such as sleep spindles, and possibly, the 
abnormal electroencephalographic 3 Hz spike and 
wave rhythm seen in human absence seizures. 
Although GBP is most effective in the treatment of 
human partial and generalized tonic-clonic seizures, 
the effect of GBP on absence seizures has been stu- 
died both in animal models of absence seizures and 
as add-on therapy in drug-resistant epileptic pa- 
tients. In animal studies using pentylenetetrazol-in- 
duced clonic seizures, GBP protected mice from 
clonic convulsions in both the S.C. Metrazol test 
(EDso 147 mg/kg) and the i.v. threshold test (120% 
control, 30-50 mg/kg) [3]. However, in a rat genetic 
model of absence epilepsy, GBP increased electro- 
encephalographic spike and wave bursts in a dose- 
dependent manner at 25 and 100 mg/kg [9]. In stu- 
dies of mouse spinal cord neurons, GBP blocked 
responses to Bay K 8644, an agonist at the dihydro- 
pyridine binding site of the L channel [28]. In hu- 
man studies, GBP reduced > 50% of absence sei- 
zures in half of the patients in one study [5], and in 
another study, GBP reduced absence seizures and 
generalized spike and wave complexes in patients 
undergoing 24 h EEG monitoring [20]. 
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In the present studies, GBP did not affect any 
component of the Ca*+ channel current subtype 
studied (T, L, or N). Since GBP did not affect 
residual current following use of both nifedipine 
and w-conotoxin, there was no evidence to suggest 
that GBP might be capable of blocking P-type 
Ca*+ channel current. These results suggest that 
GBP’s basic mechanism of action was not on vol- 
tage-dependent Ca*+ channels. 
In summary, the results of the present studies do 
not demonstrate a major effect of GBP on any of 
the several different experimental systems tested, 
even when tested at concentrations well above 
plasma concentrations which commonly range 
N 12-88 PM in clinical studies [6]. Specifically, the 
studies do not show significant effects of GBP on 
neuronal responses to applied GABA, glycine, or 
glutamate. At high concentrations, GBP shows a 
variable enhancement of NMDA responses, how- 
ever, GBP produces no reductions in NMDA re- 
sponses under the conditions tested. GBP does 
not show effects on sustained repetitive firing of 
Nat channel action potentials or on voltage-de- 
pendent Ca*+ channel currents. Each of the ex- 
perimental systems tested specific voltage- or li- 
gand-gated responses that previous animal and/or 
human studies suggested as potentially important 
in the mechanism of action of GBP. Our results 
fail to corroborate the results of previous investiga- 
tions other than those which were similar in design 
and yielded negative results. The mechanism of ac- 
tion of GBP on neurons involved in the generation 
of seizure activity remains to be determined. 
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